Open Label Trial of INCB07839 to Determine Effect and Safety of INCB007839 Plus Trastuzumab in HER2 Positive Metastatic Breast Cancer

This study has been terminated.

(Incyte suspended development of the compound.)

Sponsor:

Information provided by (Responsible Party):

Incyte Corporation

ClinicalTrials.gov Identifier:

NCT00864175

First received: January 26, 2009

Last updated: January 20, 2012

Last verified: January 2012

No Study Results Posted on ClinicalTrials.gov for this Study

Study Status:	This study has been terminated.
Study Completion Date:	October 2011
Primary Completion Date:	June 2011 (Final data collection date for primary outcome measure)
Certification or Request for Extension to Delay Results Received:	June 18, 2010